ΑBSTRACTS ΟF 6 CONFERENCE - enee.gr · Όταν η nihss αφαιρέθηκε από την...

-

2

01

6 /

Jan

uar

y -

Feb

ruar

y 2

01

6

6 / BSTRACTS F 6TH GREEK NATIONAL STROKECONFERENCE

25 - 1

Vol. 25 - Issue 1

6 8

( 2015 - - 24/ 6 - 2 41

10, 115 28.: 210 72.47.056 - Fax: 210 72.47.556www.enee.gr [email protected]

ENE

: . : . . : . : . : . . .

. - .

. . . . . N. A

. - .

-

.

: 10, 11528

KAI H

.. 7136 71, .: 210 34 10 436 - 1, Fax: 210 34 25 967www.lyhnia.com

: 7159ISSN 1106 - 3106

25, 1, - 2016

3

ABSTRACTS

BSTRACTS F 6th GREEK NATIoNAl STRoKE CoNFERENCE (HEllENIC SoCIETY oF CEREBRoVASCUlAR DISEASES) 8

ERRATUM

GUIDElINES oN THE PHARMAColoGICAl TREATMENT oF EPIlEPSY - UPADETD 2015 - TABlE 2 (NEURoloGIA, Vol 24:6) 41

NEWS

Contents

Official Journal of the Hellenic Neurological Society10, Alkmanos str., AthensTel.: 210 72.47.056 - Fax: 210 72.47.556www.enee.gr [email protected]: [email protected]

HNS BOARD OF DIRECTORS

President: . VadikoliasVice President: . KilintireasGen Secretary: . AvramidisTreasurer: J. RudolfMembers: . Artemis K. Voumvourakis . Triantafillou

EDITORS

. Vadikolias - G. Tsivgoulis

CO-EDITORS

V. KimiskidisJ. RudolfE. DardiotisG. DeretziT. Avramidis. rtemis

HNS SECRETARIAT

G. Tigaraki - . Sintrofiou

TECHNICAL ASSISTANCE - WEB-EDITION

D. Mantzaris

OWNER

HEllENIC NEURoloGICAl SoCIETY10 Alkmanos str, Athens11528 - Greece

PRINTED EDITION AND PDFs

lychnia S.A.7 Andravidas str., Athens136 71, Hamomilo Aharnonel.: 210 34 10 436 - 1, Fax: 210 34 25 967www.lyhnia.com

SUBSCRIPTION FEES

HNS Members Free

Volume 25:1 January - February 2016

InternatIonal advIsory Board

Alexis ArtzimanoglouProfessor of Neurology & Child Neurology at the University Hospital of Lyon France

Constantin BourasProfessor, University of Geneva, Geneva, Switzerland

George DellatolasUniversite Paris Descartes, Institute de Psycologie

Ludwig KapposProfessor, Neurology and Research Group, Department of Biomedicine,University Hospital, Basel, Switzerland

Spyros KolliasProfessor, Institute of Neuroradiology, University Hospital of Zurich

Michalis KoutroumanidisMD, Dept. of Clinical Neurophysiology and Epilepsies Guys St Thomasand Evelina NHS Foundation Trust London, UK

Dimitrios S. MonosProfessor, Pathology and Laboratory Medicine, Perelman School of Medicine at the Universityof Pennsylvania, Immunogenetics Laboratory at the Childrens Hospital of Philadelphia

Nikolaos RombakisProfessor, Neuroscience and Psychiatry, Medical School Mount Sinai, New York

Anton ValavanisProfessor, Institute of Neuroradiology, University Hospital Zurich, Switzerland

25, 1, - 2016

6

H , , : ,

8

25: 1-2016, 8-40

01*

, , . , , , - , , , , .

, , , ,

: (). , .

: . E: 790

(41,0% , 79,46,8 ). National Institutes of Health Stroke Scale (NIHSS). 126 mg/dl . ( Rankin 2 6) .

: . - , NIHSS . NIHSS , , , . - , NIHSS . NIHSS - , , , , . : .

* .

9

25: 1-2016, 8-40

02

()

1, 2, 3, . 1, 4, Vijay K. Sharma5, 6, Robert Mikulik3, 7, 8, Milija Mijajlovic9, 1, 1, Simon Faissner6, 4, 1, 1, 1, Andrei V. Alexandrov2

1 , , , , , 2 Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, 3 International Clinical Research Center, St. Annes University Hospital in Brno, Brno, Czech Republic, 4 , , , , 5 Division of Neurology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 6 Department of Neurology, St. Josef-Hospital, Ruhr University, Bochum, Germany, 7 Neurology Department, St. Annes Hospital and Masaryk University, Brno, Czech Republic, 8 , , , , 9 Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia

: () . - , .

: - .

E: ( NIHSS ), (, 0-1 mRS), 1 . , (propensity score matching).

: 192 (37.2%) 516 ( :6513 , 60.8% , NIHSS : 9). , 1 , - (HR=0.11, 95%:0.02-0.46) 1 (HR=0.24, 95%:0.08-0.75).

: , .

10

25: 1-2016, 8-40

06

NEDAFISP-2 NEURO PROJEC

, , , , , , , , , , , , , , , , , , , .

-

: () . (). . NEDAFISP - ( 1mission 1million). NEDAFISP-2- euro

:

: . : () - : , , , , . . 24 (1-3). . NEDAFISP.

: 1059 450 (340 110 ). (=340) 66 (19.4%) /monitoring . - 384 87 (22.6%) 27.3% 10.9% . 1 Holter 68/87 (78.2%), 2 15/87 (17.2%) 4/87(4.6%) 3.

: 24 . (27%) - ( ). (>10%) .

11

25: 1-2016, 8-40

07

(VOXEL BASED MORPHOMETRY VBM)

, , , , , , , ,

, , E , -MRI,

: H . , , . . - .

(Voxel-based morphometry-VBM) , . .

: (GM), , .

Y : 1 1.5 Tesla (Intera, Philips Medical Systems). (Statistical Parameter apping - SPM-8 Wellcome Department of Cognitive Neurology, UK) MATlAB (Mathworks, Sherborn, MA, USA). . 65-73 (=7) (>90%) . (=7) . . .

: 2 . . , , . - , , .

: , - , , . , .

12

25: 1-2016, 8-40

08

BARTHEL INDEX :

,

: Barthel Index (BI) .

: , - BI .

: 57 , . 37 20 , 67,7 ( 6.7SD) 54-85 .

BI - (rho) Spearman.

: BI (r=0.967, p

13

25: 1-2016, 8-40

01

- : -

1, . 2, 3, 1, 1, 1, 2, 2, 2, 2, 4, Adam Arthur5, Andrei V. Alexandrov6, 2, 6

1 Metropolitan, , , 2 , , ,, 3 , , , 4 , , , 5 Semmes-Murphey, Tennesee, Memphis Tennessee, , 6 Tennesee, Memphis Tennessee,

: () () (), - ().

: - -- () .

E: 2 ( ) . (acoR) ( ) 3 2 . - - Cochrane.

: (MR ClEAN, ESCAPE REVASCAT, 1021 ) (833 &188 ). - , (acoR=1.85, 95% CI: 1.37-2.49; p

14

25: 1-2016, 8-40

02

: ,

1, 1, 1, 1, 1, 1, 1, 2, 1, 3, 1, 1, 1, 1, 1

1 , , 2 , , 3

: () () Valsalva . .

: ( Hodges & Warlow) - . . Doppler . 3 Valsalva ( 5sec). Valsalva. >0.88 sec.

: 9 (33% , 633). 3 (33%, 2 1 ) Valsalva. - . ABES Valsalava . ABES - (8 ) (5 , p=0.116).

: .

15

25: 1-2016, 8-40

03

() ()

, MD1, , D2, , MD1, , MD1, , MD1, , MD1, 3, . , MD1, 4, , MD1, , MD1, 5, , MD1, , MD2, , MD1

1 , , 2 , , 3 , , 4 , , 5

: >30sec . 30sec.

: (30sec) () .

E: 3 . NIHSS. 24 Holter . 2 . . 2 (30sec & >30sec). (mRS-score 0-1) .

: 184 ( NIHSS-score 4, : 2-7). 23 (13%, 95%:8%-18%). 57% (N=13). 2 (p>0.2) , . (p>0.4).

: H .

16

25: 1-2016, 8-40

04

(): SITS (SAFE IMPLEMENTATIONS OF TREATMENTS IN STROKE)

,1,2 ,3,4 ,2 ,3 ,3 - ,3 ,1 ,5 ,5 ,3 ,5 ,1 ,2 5, 1

1 , , , 2 , , , 3 , , , , 4 , , , 5 , ,

: () () . .

: - SITS.

E: - 2015 SITS. - , (), SITS-MoST) . ( , 24 7 ) ( 0-2 Rankin).

: 10 ( 5316 , 70% -,) [1 (=5), 2 (=2), (=2), (=2)] 2 . - 269 ( 210-458). 90% , (p

17

25: 1-2016, 8-40

05

. 24

, ,

, ... ,

: 60 (15-30%). 135-400/100000/ 500-600/100000. , 4,5 .

: , .

/ : 27 , SITS. NHISS 24 . , 21 (78%) 1 NHISS, 4 (15%) , 2 (7,5%) . , 3 (11%) ( -) 3 . ,, .

/: . - , - .

07

:

, , , ,

..., ....

: 4,5 , .

: H , 16 .... .

/: 13 ( : 61 , 5 ). SITS-ISTR. 145. : 1) : 100, 2) CT : 26, 3) (door-to-needle): 62. - ( NIHSS : 12) ( NIHSS : 3). : 36%, 36%, 18% 10%. 12/13 (92,3%) (mRS 0-1) 3 .

18

25: 1-2016, 8-40

(7,7%) , 54h , (mRS 2 3 ).

: , - DNT SITS-ISTR. .

08

STENTINg : -

1, 2, . 2, 3, 1, 1, 2, 2, 2, 1, Andrei V. Alexandrov4, 2, 4

1 Metropolitan, , , 2 , , , , 3 , , , 4 Tennessee, Memphis Tennessee,

: () () () -.

: - -- () .

E: (677 ) -. 30 , : , , . - - Cochrane.

: ( -) 30 . . .

: .

19

25: 1-2016, 8-40

01

. 1, 2, 3, 4, 5, 6, 7, . 8, . 1, 2, 1, 2

1 , , , , 2 , , , , 3 , , , , 4 , , , , , 5 Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA 6 International Clinical Research Center, St. Annes University Hospital in Brno, Brno, Czech Republic, 7 , , , , 8 , , ,

: ().

: - , .

E: .

: 518 , - 88 . 69.3%. (), () 30.6% 22.7% , . / 26.1% , 14.7%. 2.3%, 3.4% 2.3% , . 9.1% . . , , .

: , , .

20

25: 1-2016, 8-40

02

: -

. 1, 2, 3, 4, 5, 5, - 5, 6, 7, 8, 1, 1, 2, 1, Anne W. Alexandrov9, 10, Andrei V. Alexandrov9, 1, 9, 11

1 , , , , , 2 , , , , 3 , , , , 4 , , , , 5 , , , , , 6 , , , , , 7 , , , , 8 , , , , , 9 Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA, 10 Australian Catholic University, Sydney, Australia, 11 International Clinical Research Center, St. Annes University Hospital in Brno, Brno, Czech Republic

: - () .

: - .

E: - .

: 4 , 15.240 (apixaban, dabigatran, rivaroxaban) . - , dabigatran rivaroxaban ( =0.28, 95%, : 0.11-0.75), rivaroxaban dabigatran ( =0.14, 95% CI: 0.03-0.74). apixaban -. , .

: . - .

21

25: 1-2016, 8-40

03

. 1, 2, Rohini Bhole3, 4, 2, Nitin Goyal3, - 4, 5, 4, . 2, Anne W. Alexandrov3, 6, 1, 1, 1, Andrei V. Alexandrov3, 1, 3, 8

1 , , , , , 2 , , , , 3 Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA, 4 , , , , , 5 , , , , 6 Australian Catholic University, Sydney, Australia, 7 , , , , , 8 International Clinical Research Center, St. Annes University Hospital in Brno, Brno, Czech Republic

: - (Embolic Strokes of Undetermined Source, ESUS) .

: - ESUS .

E: . , - .

: 61 ESUS [ : 4412 , 49% , NIHSS-score=5]. - 52% (95% : 40%-65%) . ( , , ) 10 (16%, 95%: 9%-28%) . 3562 - (12 ) 8.7% (95%: 7.3%-10.4%). , (p=0.315) [6.9% (95%: 4.9%-9.6%)], ESUS [8.1% (95%: 3.4% -18.1%)] AEE [9.4% (95%: 7,5%-11.8%)].

: ESUS.

22

25: 1-2016, 8-40

08

C-

1, 1, 1, 1, 1, 3, 1, 1, 1, 4, A 1, 5, 1, 1

1 , , , , , , 2 , , , , , , 3 , , , , , 4 , , , , , 5 , , ,

: C- (CRP) (). CRP ().

: (3) . NIHSS . 10 NIHSS. CRP - 48 . CRP 6 mg/dl. Spearmans correlation coefficient (r) .

: 186 (66% , 5712 ) CRP 48 . CRP - 68 (36%; 95%CI: 29%-43%) (27% 8%; p=0.001). CRP, CRP (r:+0.352; p=0.004). CRP -, , - (oR: 4.53, 95%CI: 1.10-18.66; p=0.037).

: CRP - . CRP .

23

25: 1-2016, 8-40

09

2014

. , . , . , .

: T () 2 1 .

-E: 2014 -. , 1 .

: 325 (170 155 ) . 300 (262 38 ) 25 (15 - 10 ). ToAST : ) (= 128), ) (=126), ) (=55), ) - (=15) ) (1). (85%), (25%) (25%, 5% 20% ). 7% 1 Rankin (mRs): 5% 6, 20% 0, 35% 1-2, 30% 3-4 10% 5. 90% 10% .

:

02

: ... , .

: ... . .

E: 2014 2015. : SF-36 SS-Qol. 80 .

: ... . ... . , , .

: ... -

24

25: 1-2016, 8-40

... , . ... .

03

-

, , , ,

: (WMH) (MRI) (SVD) . - . WMHs duplex (CDU).

: MRI WMHs. CDU. ( ) ( ), (> 50%) - , - .

: 52 . - WMH-score IMT (CCA) .

: SVD , WMHs, .

04

ARMEO SPRINg

, , , , , , ,

, . ,

: . . .

-: 10 (5 5 ) , 65-83 , . 4 6 . -

25

25: 1-2016, 8-40

5 /. 2 Armeo Spring 5 /. 2 . - : oxford scale Upper extremity functional index (U.E.F.I.) Workspace program Armeo Spring.

: oxford scale: 1+ U.E.F.I. score: 25,8/80. oxford scale 1+ 2+ U.E.F.I. score 42,9/80. Workspace program Armeo Spring. oxford scale (3+/ 1) U.E.F.I. score:58,4/80.

: . .

05

. 1, 1, 1, 1, 2, . 1, 3, 1, 3

1 , , , , 2 , , , , 3 , , ,

: . - .

: () () - 2008-2014. , , 2011, .

: 2011 ( 57.6 13.5) (p=0.001), (p=0.028), (p=0.002), (p

26

25: 1-2016, 8-40

08

. , .

: T () - .

-E: 2014 - . , , , .

: 80 (50 30 ) . 75 5 . ToAST : ) (= 28), ) (=26), ) (=20), ) - (=5) ) (1). (85%), (35%) (25%). 3 , 10 , 5 20 holter- . 2 1 , . , 10 CHADSVASc>2 .

: - .

09

TIMED UP & gO TEST

, , , , , , ,

,

: , . , .

: Timed up & go, TUG MMSE . - (>1) , - . .

27

25: 1-2016, 8-40

: 17 (=17.12, SD=10.361) (=12.2, SD=5.31). - pearsons r. , r=-.486. (>12sec) - MMSE. .

: . .

30

25: 1-2016, 8-40

04

BEHCET

, , , ,

, ,

: . . Behcet . - , , , , .

: 45 , , , . CT MR - , MRI . . . , , . HlA-B51, Behcet.

: Behcet , . , . , , - - .

06

DUPLEX :

1, 1, 1, 1, 2, 2, 3, 1

1 Metropolitan, , , 2 , , , , 3 Tennesee, Memphis Tennessee,

: (). duplex (TCCDS), (), / .

: TCCDS .

E: 3 , , 24, (). 2 ( 1 2) - () ( 3)

31

25: 1-2016, 8-40

. TCCDS, / , -.

: TCCDS 2 3 , 1 . 1 2 24 .

: - . TCCDS .

07

- , , , , ,

,

: (>50%) , -. . . .

: 58 , , , - 2015 2. , , 40mmHg. Triplex Doppler . MRA , - . MRI . . .

: . , , , , .

32

25: 1-2016, 8-40

08

1, 1, 1, 1, 2, 1

1 , 1

: , , . , .

1 : , 49 , , , . - MRI , 10, . .

2 : , 61 , -, , , , MRI , , . , , .

: - . . MRI , , .

06

, , - ,

..

: , - , .

: 43 , , , - , . , -. , .

, . .

33

25: 1-2016, 8-40

, , , .

, -. triplex . . .

MRI , 14 , . , - .

: , -, , .

04

D-DIMERS :

1, 1, 1, 1, 1, 3, 1, 1, 2, . 1, 1, 1

1 , , 2 , , 3 , ,

: . , D-dimers .

: 1: 49 , , , . D-dimers : >20000 ng/ml (.. < 500ng/ml). MRI : . Doppler : - . CT -: , (, ) . (CA19.9: >10000 U/ml). .

2: 60 , , , , - , . - . D-dimers : 6502 ng/ml. : , Doppler . CT - . . , .

: D-dimers .

34

25: 1-2016, 8-40

05

: .

1, 4, 1, 1, 1, 1, 1, 2, 3, 1, 1

1 , , 2 , , 3 , , 4 , ,

: - . .

: 1: 60 , - ( ) . triplex - (

35

25: 1-2016, 8-40

06

-

, , , , , , , , , ,

,

: To () 2% () . , 2 6 , . , , . AHA/ASA (2016) (IIa/C) 4,5 . ().

: , 54 , , - (NIHSS=11). 40 (). - . . 190 . . . NIHSS 2. 3 Rankin Scale Score 0.

: . - .

36

25: 1-2016, 8-40

07

:

1, - 2, 3, -4, 1, 3, 1, 1

1 - , 2 . , 3 , 4 St. Josephs Hospital Bochum

: - , .

: 63 PoEMS, - , , .

, (MMSE =11/30 MoCA=6/30), , , , -, , , .

, , .

, 2 FlAIR, - , , .

(MMSE =15/30 MoCA=6/30) MMSE 22/30 .

: , . , - ( ).

08

:

1, 1, 1

1

: (posterior reversible encephalopathy syndrome, PRES) Hinchey 1996. , , , , , .

: 48 , , - ,

37

25: 1-2016, 8-40

, . , , - 2 . , (MRC : 4+). ( ) Reil. , . . , , . ( , ), . , , - , .

: , PRES - , . , , ( ) . , , , . , - , PRES.

09

1, 2, 1, 1, - , , 2, 2, 2, 2 1 , , , 2 , ,

: (AHA/ASA), 2014, ().

: , AHA/ASA, , .

: , 76 , NIHSS Modified Rankin Scale , 18 , , , , , , , . , , , . ,

38

25: 1-2016, 8-40

/ Guidelines on the pharmacological treatment of epilepsy

. /, / / , / / .

: 328% 70%. Modified Rankin Scale 3.

: . , , 1.5 , .

01

CASASIL: (8)

1, 1, 1, 1, 1, 1, 2, 1

1 , 2

: CADASIl ( ) . .

: 39 , . . - , - . MRI . MRA . Cadasil . Cadasil ( Notch3 , Arg1031Cys 19).

: 8 Cadasil. 4, 5 19, .

06

:

1, 2, 2, 3, 3, 1

1, 2 . . , 3 . .

: , .

39

25: 1-2016, 8-40

: , 69 8. : , , , , . , IgM . .

. . , (MRI), .

(7-8) . :

. , .

, . , .

7-12 . . , , , , , -, , , , . 10%.

07

, ,

- , -, ,

: , , . , Broca , .

: 45 , , , , , /. . , . MRI - . triplex , . MRA-, . , , .

: , .

40

25: 1-2016, 8-40

10

- -

, , ,

: , . 30% . . , , , , - . , . . - . . . .

41

25: 1-2016, 41

( )

*

**

( , , )

( )

* , .** .

.

- 2015

gUIDELINES ON THE PHARMACOLOgICAL TREATMENT OF EPILEPSY - UPDATED 2015ellenic Neurological Society in collaboration with the greek League angainst Epilepsy and the Hellenic Paediatric Neurology Association

AbstractAbstract not available (article in greek).

- 2015

gUIDELINES - UPDATED 2015

6 , : 24

ERRATUM IN 6th VOL, ISSU: 24

www.enee.gr

. . . . 4.8 . 1. TYSABRI 300mg, . 2. ml 20mg natalizumab. natalizumab 4 DNA. 2,6mg/ml natalizumab. To TYSABRI 2,3 mmol ( 52 mg) . 100 ml 9 mg/ml (0,9%) 17,7mmol ( 406 mg) . 3. . , . 4. 4.1 TYSABRI : 18 - .

( ) - . 1 , 9 T2 (MRI) 1Gd . , .

18 , 2 , 1

Gd T2 . 4.2 TYSABRI , . TYSABRI TYSABRI (. ). 2 , TYSABRI, (PML) , , PML. . natalizumab , .. . , natalizumab. (.. , , ). , . , TYSABRI, (. 4.4). TYSABRI 300mg 4 . 6 . natalizumab 2 , . 2 . PML, , TYSABRI JC (. 4.4). . . 4.4. TYSABRI 65 . . . TYSABRI 18 (. 4.3). . , 6.6 . 1 1 . TYSABRI (bolus) . 4.3 natalizumab . (PML). , ( , .. , . 4.4 4.8). - . , . 18 . 4.4 (PML) TYSABRI PML JC, . PML, TYSABRI . , PML. PML. JC. , 2 . TYSABRI 4 ,

PML . TYSABRI. JC PML TYSABRI. JC PML JC. PML (. JC TYSABRI 2 ) PML. , TYSABRI . PML , . JC TYSABRI. JC TYSABRI TYSABRI . JC PML, JC, . 6 JC. JC (ELISA) PML. JC . TYSABRI, (MRI) ( 3 ), . . 2 PML TYSABRI. PML, PML. , , PML. , , ( ), () DNA JC , (. ). PML ( , , / ), natalizumab . PML, (.. ). , . PML TYSABRI PML . PML, TYSABRI. PML, TYSABRI . PML, . PML IRIS ( ) IRIS PML TYSABRI TYSABRI, .. . IRIS PML, . PML TYSABRI IRIS PML ( , . ). , TYSABRI, Crohn, . , TYSABRI . TYSABRI (. 4.8). TYSABRI -. , , , , Tysabri (. 4.8). , TYSABRI . TYSABRI TYSABRI. , TYSABRI . TYSABRI , TYSABRI . TYSABRI . TYSABRI . , , TYSABRI. , (. ). TYSABRI, (. 4.8). 1 . , , , ( ) ( ) , TYSABRI. , . 1 (. 4.8). . TYSABRI . TYSABRI. TYSABRI . TYSABRI , , (. 4.3). PML. . TYSABRI (. 4.3). 3 , . TYSABRI. natalizumab. , , 6 , , TYSABRI (. 4.8). TYSABRI, natalizumab / , , 6 , Tysabri. . , . , TYSABRI. TYSABRI. , . , TYSABRI . TYSABRI natalizumab, natalizumab

(.. ) 12 . natalizumab. , . . natalizumab . natalizumab. . TYSABRI To TYSABRI 2,3 mmol ( 52 mg) . 100 ml 9mg/ml (0,9%) 17,7mmol ( 406 mg) . . 4.5 TYSABRI - (. 4.3). , 60 ( ) KLH (keyhole limpet haemocyanin- Megathura crenulata) TYSABRI 6 . . 4.6 , . , , TYSABRI . TYSABRI 355 . 316 , 29 . 29 . . TYSABRI. , TYSABRI . , TYSABRI . TYSABRI, TYSABRI. - TYSABRI TYSABRI. TYSABRI . natalizumab / . TYSABRI. . natalizumab . natalizumab . 4.7 TYSABRI . , , . 4.8 1.617 natalizumab 2 ( : 1.135), 5,8% natalizumab ( : 4,8%). , 43,5% natalizumab ( : 39,6%)1. natalizumab , , , . natalizumab 0,5% . MedDRA MedDRA. : (1/100

. .

. . 4.8 .1. LEMTRADA 12 mg .2. 12 mg 1,2 ml (10 mg/ml). DNA , ( ) . , . 6.1.3. ( ). , pH 7,0 - 7,4.4. 4.1 LEMTRADA - (RRMS) (. 4.4 5.1). 4.2 LEMTRADA . , . / . LEMTRADA LEMTRADA (. ). LEMTRADA 12 mg/, 2 . : 12 mg/ 5 ( 60 mg) : 12 mg/ 3 ( 36 mg), 12 . . 2 (. ) 48 (. 4.4). LEMTRADA 3 . , 1.000 mg 3 LEMTRADA. , / LEMTRADA. 1 LEMTRADA (. 4.4). , 200 mg . 55 . . LEMTRADA . LEMTRADA 0 18 . 10 . . LEMTRADA . 4 . , . 6.6. 4.3 6.1. (HIV). 4.4 LEMTRADA . LEMTRADA , . , , 48 LEMTRADA. , (ITP), , , (.., ). , . (ITP) ITP 1% . , ITP . ITP 14 36 . ITP ( ) , , (.. , ) . anti-GBM (. ) . . , 48 . , ITP. ITP, . ITP, . ITP ITP, . LEMTRADA ITP . , (anti-GBM), 0,3% 39 LEMTRADA. 2 anti-GBM. , . ,

/ . , anti-GBM. ITP (. ) . . anti-GBM / , . , 48 . , 48 . , / , . . , . LEMTRADA . 36% LEMTRADA 12 mg , 48 LEMTRADA. LEMTRADA -1 (IFNB 1a). , LEMTRADA . . . ,

() , . , , LEMTRADA (12%) IFNB-1a (3%) . LEMTRADA . LEMTRADA 1 . , 200 mg . LEMTRADA . , LEMTRADA . LEMTRADA . LEMTRADA (HBV) C (HCV), . HBV / HCV LEMTRADA, LEMTRADA HBV / HCV, - . , LEMTRADA / . , , . LEMTRADA . 4 LEMTRADA (. 4.6). 6 LEMTRADA. LEMTRADA . LEMTRADA LEMTRADA. / - , LEMTRADA, - (VZV) VZV. VZV LEMTRADA. VZV, LEMTRADA 6 . 48 LEMTRA-DA : ( ) ( ) ( ) , ( 3 ) , . LEMTRADA LEMTRADA, (-), , (.. 30 mg) . , . , ( ), , anti-GBM . , , , , Guillain-Barr , . Coombs . ---, . , , , , , , , , . , . , , , , . () - . - . . , . Ep-stein-Barr Epstein-Barr . 4.5 LEMTRADA . , - 28 LEMTRADA. 4.6 , 30 . , LEMTRADA 4 . LEMTRADA . LEMTRADA . IgG

. (. 5.3). . (. 4.4 ) . , . Graves, Graves. . . . , LEMTRADA 4 . , . LEMTRADA . - 13 ( 12 mg 24 mg), , , , . CD52 . (. 5.3), . 4.7 LEMTRADA . 24 LEMTRADA. () (.. ) . 4.8 1.188 - (RRMS) LEMTRADA (12 mg 24 mg) , 2.363 - 24 . (ITP, , , ), . 4.4. LEMTRADA ( 20% ) , , . 24 RRMS LEMTRADA 12 mg/ 5 3 12 . 0,5% / () () (MedDRA). : ( 1/10) ( 1/100 < 1/10) ( 1/1.000 < 1/100). , . 1: 1, 2 3 0,5% LEMTRADA 12 mg

/

,

, , , , , , ,

*,

*, ,

*,

*, , ,

, , , *,

Basedow, , , , ,

, *, , , , *

,

,

*

*

*

, ,

, , ,

, ,

, , ,

,

Lemtrada SPC 21X28.indd 2 2/2/15 1:13 ..

(*) 1 . , 0,5% (. 4.4). . - . : 284 GR-15562 , : + 30 21 32040380/337 : + 30 21 06549585 : http://www.eof.gr 4.9 , 60 mg LEMTRADA ( ) (, ). LEMTRADA / . . .5. 5.1 : , ATC: L04AA34. DNA CD52 , 21-28 kD. IgG1 , (). 150 kD. CD52, T (CD3+) B (CD19+) , . CD52 , . , T B . LEMTRADA . , , : - , - T - T B - (, , , ) LEMTRADA , . LEMTRADA , 1 ( 3). , 6 . CD3+ CD4+ , 12 . 40% (LLN) 6 , 80% LLN 12 . , , , LEMTRADA. LEMTRADA 3 , , , RRMS. 1 2, / 2 3 .

* 1 - 6 .

/

,

*, , , , ,

, , , , , ,

,

,

*, *, *, , , , ,

*, *, *

*, *

,

(),

1

CAMMS323 (CARE-MS I)

33

2/1,6

2,0

, 2 2 .

2

()

/

( 1 )

2

EDSS

2: 1 2

2

CAMMS32400507 (CARE-MS II)

*

35

4,5/3,8

36

28%

2,7

1

CAMMS323 (CARE-MS I)

0,45 (0,32, 0,63) 54,9

(p

, 1 (CAMMS323) LEMTRADA 12 mg/ LEMTRADA ( 61%, p=0,0056) ( 58%, p

. . ..4.8.1. AUBAGIO14mg2. 14mg.:72mg().,.6.1.3. (). , , , (14).4. 4.1 AUBAGIO (). ( 5.1 ).4.2 .:AUBAGIO14mg.: :AUBAGIO65 , . : , . . (.4.3). :.(.4.3). : AUBAGIO 10 18 . 10 . . : ..AUBAGIO.4.3 6.1.( C Child-Pugh). , , 0,02 mg/l (. 4.6). (. 4.6). (.4.6).,..AIDS.,,. , (. 4.4). , .,...4.4 : : (ALT/SGPT). : : (ALT/SGPT) (..)..,80,02 mg/l, , 2. (. 4.6 5.2 ).(.4.8).6 . -68,, , , , , / . ALT(SGPT)2-3-,. ( 3 ULN). . , . , , .. . . (.4.8).. , .,., (. 4.8). ,AUBAGIO,,AUBAGIO.,.AUBAGIO.AUBAGIO/ . AUBAGIO ,

.,AUBAGIO. (ILD) .,ILD,,.ILD,ILD.,,,.15%(.4.8).,AUBAGIO,AUBAGIO, (.. ). ,/,.,(.) . , , AUBAGIO ..,, Stevens-Johnson (DRESS). . / , (Stevens-Johnson -Lyell),.(.4.3).: AUBAGIO (. 4.8). AUBAGIO. , , . . AUBAGIO , AUBAGIO . ()()AUBAGIO.. , .., , , ..AUBAGIO,,,.,,,2-3, AUBAGIO . , AUBAGIO.,6 1 2 . AUBAGIO .,, . , t1/2z 19 14 mg. AUBAGIO, 5(3,5,),AUBAGIO.,,. AUBAGIO , ,Lapp-.4.5 , . P450(CYP):(600mg22)(CYP2B6,2C8,2C9,2C19,3A), P- [P-gp] [BCRP], (70mg) 40% . CYP,,, ( St. John), . , , . / . CYP2C8: Cmax AUC ( 1,7 2,4 , ), , CYP2C8 in vivo. , CYP2C8, ,,,. : 0,03 mg 0,15 mg CmaxAUC0-24 ( 1,58 1,54 , ) Cmax AUC0-24 ( 1,33 1,41 , ) . , . CYP1A2: Cmax AUC ( CYP1A2) 18% 55%, ,

1

Aub_Anzeige 21X28 SPC JULY 2015 NEW.indd 1 10/9/15 1:50 ..

CYP1A2 in vivo., CYP1A2 ( , , ), . S-, CYP2C9.,25%(INR).,, INR. 3 (3): CmaxAUC(1,43 1,54 , ) , OAT3in vivo.,OAT3,,,, , , , , , . BCRP / B1 B3 (OATP1B1/B3): CmaxAUC ( 2,65 2,51 , ) .,HMG-CoA.,50%.BCRP(..,,,,)OATP,HMG-Co(..,,,,,,), . . 4.6 , (.5.3). .(.5.3). . (.4.3)., 0,02mg/l. , . , ,,,,. ,,., , 0,02 mg/l (. ): , 0,02mg/l8,, 2 0,02mg/l. , .0,02mg/l,14.0,02mg/l,. , (.7).: 8 g 3 11 4g,,8g,,,,50g1211.,,14,0,02mg/l., . . .,. (. 5.3). ,.4.7 AUBAGIO . , , , .,.4.8 2267(11557mg111214mg)672(10451002 7mg 14mg,) (110 ) (). . . 2047 . , :,ALT,.,,,. AUBAGIO .:(1/10)(1/100

,,, ,13,9% 14mg,5,1% . ( ) 6121139(87,1%)14mg.1,3%14mg,0,1%. :

ALT3xULN.3xULN.6 . . : - >140mmHg19,9%14mg/,15,5%->160mmHg3,8%14mg/,2,0%->90mmHg21,4%14mg/,13,6%.,14mg(2,7%)(2,2%).0,2%. (WBC) (3ULN 66/994(6,6%) 80/999(8,0%)

>5ULN 37/994(3,7%) 31/999(3,1%)

>10ULN 16/994(1,6%) 9/999(0,9%)

>20ULN 4/994(0,4%) 3/999(0,3%)

ALT>3ULNTBILI>2ULN 5/994(0,5%) 3/999(0,3%)

1 ( , ITT)

****p

C

M

Y

CM

MY

CY

CMY

K

Ebixa kx 21x29cm SPC.pdf 12/2/2013 5:59:16

C

M

Y

CM

MY

CY

CMY

K

21x29_nemdatine.pdf 1 2/11/16 1:20 PM

C

M

Y

CM

MY

CY

CMY

K

Ebixa kx 21x29cm SPC.pdf 12/2/2013 5:59:16

: 6, 12133 , : 210 5777140, fax: 210 5788791, e-mail: [email protected], www.farmasyn.gr . : & 27, 56224 , : 2310 703856, fax: 2310 703178, e-mail: [email protected]

01

2016

Memantine/SandozMemantine

ad memantine 21x29.indd 1 21/1/16 9:46 AM

56 - - -

19-12 M 2016: 14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy, , www.ad-springfield.com

17-20 2016: 10th World Congress on Controversies in Neurology (CONy), lisbon, Portugal, http://www.comtecmed.com/cony/2016/default.aspx

8-10 A 2016: 10 , , www.epilepsycongress.gr

13-15 2016: 25th European Stroke Conference, Venice, http:// www.eurostroke.eu

15-21 A 2016: 68th American Academy of Neurology, https://www.aan.com/conferences/2016-annual-meeting/

10-12 M 2016: 2nd European Stroke Organization Conference, Barcelona, http://esoc2016.com/

11-14 M 2016: 42o E , , http://www/mednet.gr

20-21 M 2016: 4o Forum Vancouver : American Academy Neurology Meeting 2016 , http://www.gk.gr

28-31 M 2016: 2nd Congress of the EAN, Copenhagen, http://www.eaneurology.org/Welcome-to-Copenhagen-2016.2122.0.html

06-10 Io 2016: 27th Summer Stroke School, http://mozdaniudar.hr/ljetna-skola/

09-12 Io 2016: 10o , , http://www.conferre.gr

19-23 2016: 20th International Congress of Parkinsons Disease and Movement Disorders, Berlin, Germany, http://www.neuropenews.org/?ai1ec_event=20th-international-congress-of-parkinsons-disease-and-movement-disorders-2&instance_id=1469

11-15 2016: 12th European Congress on Epileptology, Prague, http://www.epilepsycongress.org/12th-european-congress-on-epileptology-prague-2016/

14-17 2016: Ectrims Congress, london UK, http://www.ectrims.eu/annual-ectrims-congresses/

23-25 2016: , , www.enee.gr

2016

, fax : 210 7247556 e-mail: [email protected]

ONOMATE:

.............................................................................................................................................................................................................

.............................................................................................................................................................................................................

:

:

.. ..................................................... .........................................................................................................................

.: .................................................................................................................................................................................................

:

.. ..................................................... .........................................................................................................................

.: ...................................................................................... FAX: ...............................................................................................

KINHTO: .........................................................................................................................................................................................

E :

e-mail: ..........................................................................................................................................................................................

-

- ENEE.V Video on Demand 2013 -.

- .

- European Academy of Neurology (on line journal ..) . - EAN 2016.

( ) :

( ) e-learning platform eBrain EFNS, EFNS Department-Department programme, Fellowship programme, Spring School, (European Academy of Neurology) online uropean Journal of Neurology

- - ENE.TV video on demand

.

(, - , , )

-

2016

- . 2/... 66198/1/6/2006, ... 1034//1-08-2006, .

1. : 6.000 .2. : . 4.000 (-

6 ). . , , , , , .

3. . . 1.500 2 .

4. . 1500, , . 2 .

5. . 4 200 .6. .7. - - ,

, .

. , . Microsoft Word document. : , , , .: . 250 . 3-10 . : . 400 . .-: 6 .: (Vancouver) .. Smith 1 ... Adams 2. 6 . - ..: , . .: . MS Word. . - . . : , (1975). , .

. .

( )

-

-

:

:

:

: FAX: e-mail:

,

( .. )

( MeSH Hellas- )

( 6 " ." "et al")

:

1.

2.

3. ( ,

)

4.

()

EDSS 12 (0,17 vs 0,29)1,2*42%

2 (0,23 vs 0,73)1,268%

.. 1

TYSa

d/02

.201

6

. 274, 152 32 .: 210 8771500 Fax: 210 6891918e-mail: [email protected]

: 1. Polman CH, OConnor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsingmultiple sclerosis. N Engl J Med. 2006;354(9):899-910. 2. TYSABRI SmPC. * hazard ratio = 0,58; 95% confidence interval 0,43-0,77) 42-43.

ΑBSTRACTS ΟF 6 CONFERENCE - enee.gr · Όταν η nihss αφαιρέθηκε από την...

Documents

Transcript of ΑBSTRACTS ΟF 6 CONFERENCE - enee.gr · Όταν η nihss αφαιρέθηκε από την...